Novo Nordisk Announces FDA Approval of a New Treatment for Adults and Pediatric Patients

Novo Nordisk has recently announced the FDA approval of a new treatment for adults and pediatric patients 12 years of age and older living with hemophilia A or B with inhibitors. Please click here to read the press release and learn more: